Teva Motions Denied In Patent Spat With Pfizer

Law360, New York (November 8, 2006, 12:00 AM EST) -- In a positive development for Pfizer Inc., Teva Pharmaceuticals Inc.’s pleas to exclude evidence and testimony in its patent dispute over the arthritis painkiller Celebrex were mostly denied by a federal judge on Monday.

The case began in February 2004, when Pfizer and its subsidiaries that hold three patents for celecoxib, the active ingredient in Celebrex, filed the suit alleging patent infringement in Teva’s generic version of the drug.

In the sixth and seventh in limine motions, Teva’s latest arguments against Pfizer weren’t successful.

In Teva’s...
To view the full article, register now.